You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Mantle cell lymphomas (MCL)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Follicular Lymphoma, B-Cell Lymphoma, Mantle Cell Lymphoma Trial in New York (Tazemetostat Pill)

Not yet recruiting
  • Follicular Lymphoma
  • +3 more
  • Tazemetostat Pill
  • New York, New York
    Weill Cornell Medicine/NewYork-Presbyterian Hospital
Jun 28, 2023

Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Houston (Biospecimen Collection, Follow-Up)

Recruiting
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Biospecimen Collection
  • Follow-Up
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

B-cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial (IKS03)

Not yet recruiting
  • B-cell Non-Hodgkin Lymphoma
  • +4 more
  • (no location specified)
Dec 7, 2022

CD5+ Relapsed/Refractory Hematopoietic Malignancies, Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL) Trial

Not yet recruiting
  • CD5+ Relapsed/Refractory Hematopoietic Malignancies
  • +5 more
  • CT125A cells
  • Cyclophosphamide, fludarabine
  • (no location specified)
Feb 19, 2021

Rituximab, Lenalidomide, Zebutinib ,Mantle Cell Lymphoma Trial in Hangzhou (ZR2 RDHAP)

Recruiting
  • Rituximab, Lenalidomide, Zebutinib ，Mantle Cell Lymphoma
  • ZR2 RDHAP
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Aug 8, 2023

Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma Trial in New York (Ibrutinib, Pembrolizumab)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Mantle Cell Lymphoma
  • New York, New York
    Icahn School of Medicine at Mount Sinai
Aug 22, 2022

Mantle Cell Lymphoma, Newly-diagnosed Mantle Cell Lymphoma Trial in Guangzhou (Zanubrutinib and Rituximab, R-DHAOx, Zanubrutinib

Recruiting
  • Mantle Cell Lymphoma
  • Newly-diagnosed Mantle Cell Lymphoma
  • Zanubrutinib and Rituximab
  • +2 more
  • Guangzhou, Guangdong, China
  • +2 more
May 6, 2022

Mantle Cell Lymphoma, Refractory Lymphoma Trial in Boston (Acalabrutinib, Venetoclax, Obinutuzumab)

Recruiting
  • Mantle Cell Lymphoma
  • Refractory Lymphoma
  • Boston, Massachusetts
  • +1 more
Aug 8, 2022

Blastoid Variant Mantle Cell Lymphoma, CCND1 Protein Overexpression, CD20 Positive Trial in Houston (Acalabrutinib, Venetoclax)

Recruiting
  • Blastoid Variant Mantle Cell Lymphoma
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

Malignant Non-Hodgkin Lymphomas Trial in Berne (CD34+ cell selection)

Active, not recruiting
  • Malignant Non-Hodgkin Lymphomas
  • CD34+ cell selection
  • Berne, Switzerland
    Department for Medical Oncology; University Hospital/Inselspital
Jul 29, 2021

Mantle Cell Lymphoma Trial in Houston (Ibrutinib)

Recruiting
  • Mantle Cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Nov 1, 2022

Mantle Cell Lymphoma (MCL) Trial in Australia, Canada, United States (Acalabrutinib, Venetoclax, Rituximab)

Not yet recruiting
  • Mantle Cell Lymphoma (MCL)
  • Duarte, California
  • +11 more
Jul 17, 2023

Lymphoma, Mantle-Cell, Recurrent Lymphoma, Mantle-Cell Trial in United States (ABT-199 and Ibrutinib Combination)

Completed
  • Lymphoma, Mantle-Cell
  • Recurrent Lymphoma, Mantle-Cell
  • ABT-199 and Ibrutinib Combination
  • Duarte, California
  • +3 more
May 22, 2022

Mantle Cell Lymphoma Trial in Hackensack (Lenalidomide, Ibrutinib, Rituximab)

Active, not recruiting
  • Mantle Cell Lymphoma
  • Hackensack, New Jersey
    The Cancer Center at Hackensack University Medical Center
May 3, 2022

Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma Trial (BGB-11417)

Not yet recruiting
  • Mantle Cell Lymphoma
  • +2 more
  • (no location specified)
Jul 25, 2022

Mantle Cell Lymphoma Trial in Busan (Ixazomib)

Recruiting
  • Mantle Cell Lymphoma
  • Busan, Western, Korea, Republic of
    Kosin University Gospel Hospital
Mar 31, 2022

Mantle Cell Lymphoma Trial in China (High dose, Low dose)

Not yet recruiting
  • Mantle Cell Lymphoma
  • High dose
  • Low dose
  • Bengbu, Anhui, China
  • +20 more
Jul 28, 2023

Mantle Cell Lymphoma Trial in Birmingham (Ublituximab, Umbralisib)

Recruiting
  • Mantle Cell Lymphoma
  • Birmingham, Alabama
    University of Alabama at Birmingham
Sep 8, 2021

Mantle Cell Lymphoma, MCL Trial in United States (Tafasitamab, Lenalidomide)

Recruiting
  • Mantle Cell Lymphoma
  • MCL
  • Basking Ridge, New Jersey
  • +6 more
Mar 27, 2023

Mantle Cell Lymphoma Trial in China (400mg of TQB3909 tablets, 600mg of TQB3909 tablets)

Recruiting
  • Mantle Cell Lymphoma
  • 400mg of TQB3909 tablets
  • 600mg of TQB3909 tablets
  • Beijing, Beijing, China
  • +27 more
Oct 26, 2023

Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) Trial in Beijing

Recruiting
  • Relapsed or Refractory B-cell Lymphoma
  • +6 more
  • Beijing, China
    Beijing Cancer Hospital
Feb 6, 2023

Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Italy (Consolidation with ADCT-402 (loncastuximab

Recruiting
  • Relapsed Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy (R-BAC, Rituximab - Bendamustine, Ara-C))
  • Brescia, Italy
  • +19 more
Apr 22, 2022

DLBCL, MCL, and FL Patients Undergoing CAR Therapy

Not yet recruiting
  • Follicular Lymphoma
  • +2 more
  • ClonoSEQ
  • Palo Alto, California
    Stanford Cancer Center
Apr 19, 2022

Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial (ONM-501, Cemiplimab)

Not yet recruiting
  • Triple Negative Breast Cancer
  • +13 more
  • (no location specified)
Aug 29, 2023

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma Trial in United States (TGR-1202, Ibrutinib)

Active, not recruiting
Has Results
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • Mantle Cell Lymphoma
  • Monterey, California
  • +4 more
Aug 29, 2022